Sophie Postel‐Vinay

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari et al. · Clinical Cancer Research · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +17

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté et al. · Cancer Discovery · 2017 · 776 citations

Medicine, Molecular Biology, Oncology +17

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Alice T. Shaw, Enriqueta Felip, Todd M. Bauer et al. · The Lancet Oncology · 2017 · 649 citations · Full text

Medicine, Oncology, Pharmacology +14

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im et al. · The Lancet Oncology · 2020 · 459 citations

Medicine, Oncology, Pharmacology +15

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

David Olmos, Sophie Postel‐Vinay, L Rhoda Molife et al. · The Lancet Oncology · 2009 · 339 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +16